A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL3+IDL])

Table 4 Baseline characteristics among categories of the apo A1 remnant ratio (apo A1/ [VLDL ₃ -C+IDL-C])

Characteristic	Category 1 (n=98)	Category 2 (n=310)	Category 3 (n=303)	p-value
Age (year)	68.5±9.2	67.3±9.0	68.0±9.9	0.44
Hypertension	72.4%	70.6%	55.8%	<0.0001
Hyperlipidemia	60.2%	51.3%	45.2%	0.03
Diabetes	33.7%	20.6%	18.2%	0.005
Metabolic Syndrome	53.1%	32.6%	22.8%	<0.0001
Family History of CAD	45.9%	42.9%	40.6%	0.63
Smoking	10.2%	14.5%	11.6%	0.40
Prior CAD	44.0%	36.1%	38.2%	0.43
Prior MI	5.1%	6.5%	5.3%	0.79
Presentation				0.53
Stable Angina	59.2%	65.2%	60.1%
Unstable Angina	30.6%	23.5%	29.0%
MI	10.2%	11.3%	10.9%
CAD	44.9%	41.9%	44.2%	0.80
Any Lipid Lower	27.4%	45.2%	42.0%	0.03
Statin	23.3%	42.1%	36.6%	0.02
Aspirin	42.5%	40.7%	43.4%	0.85
ACE Inhibitor	30.1%	31.2%	21.4%	0.06
ARB	16.4%	19.7%	15.1%	0.44
Beta-blocker	39.7%	32.3%	33.5%	0.50
LDL-C (mg/dL)	119.9±48.9	106.4±35.1	102.7±34.2	<0.0001
HDL-C (mg/dL)	41.7±14.9	46.1±13.7	52.7±16.6	<0.0001
Triglycerides (mg/dL)*	176.0	145.0	116.0	<0.0001
Apo A1 (mg/dL)	106.2±14.6	115.0±17.0	128.9±20.9	<0.0001
Apo B (mg/dL)	93.4±21.2	78.5±15.6	69.4±15.6	<0.0001
Apo B/Apo A1 Ratio	0.89±0.19	0.69±0.13	0.55±0.14	<0.0001
non-HDL-C (mg/dL)	158.0±55.1	137.7±37.3	128.2±37.2	<0.0001
Triglycerides/HDL-C Ratio*	4.7	3.2	2.3	<0.0001
VLDL₃-C+IDL-C (mg/dL)	37.1±7.6	24.6±5.1	14.6±3.8	<0.0001
Total Cholesterol/HDL-C Ratio	5.1±1.6	4.4±2.9	3.9±2.9	<0.0001

*Median reported due to non-normal distribution.
Apo: apolipoprotein; ARB: angiotensin receptor blocker; CAD: coronary artery disease; HDL-C: high density lipoprotein cholesterol; IDL-C: intermediate density lipoprotein cholesterol LDL-C: low density lipoprotein cholesterol; mg/dL: milligrams/deciliter; MI: myocardial infarction; VLDL-C: very low density lipoprotein₃ cholesterol.
Categories were determined by recursive partitioning and were stratified into the following: category 1: ≤3.5 mg/dL; category 2: 3.5-6.0 mg/dL; category 3: >6.0 mg/dL.

ISSN: 1476-511X